Comment on: Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood

Rana Hanna AL-Shaikh; Karen R. Jansen-West; Leonard Petrucelli; Zbigniew K. Wszolek; Mercedes Prudencio

doi:10.1002/mds.29008

Comment on: Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood

Rana Hanna AL-Shaikh, Karen R. Jansen-West, Leonard Petrucelli, Zbigniew K. Wszolek, Mercedes Prudencio

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1120-1121
Number of pages	2
Journal	Movement Disorders
Volume	37
Issue number	5
DOIs	https://doi.org/10.1002/mds.29008
State	Published - May 2022

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/mds.29008

Cite this

@article{925746fd4f934f31901493f7fb1f9eae,

title = "Comment on: Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood",

author = "{Hanna AL-Shaikh}, Rana and Jansen-West, {Karen R.} and Leonard Petrucelli and Wszolek, {Zbigniew K.} and Mercedes Prudencio",

note = "Funding Information: Z.K.W. receives partial funding from NIH/NIA and NIH/NINDS (1U19AG063911, FAIN: U19AG063911), Mayo Clinic Center for Regenerative Medicine, Mayo Clinic in Florida Focused Research Team Program; gifts from The Sol Goldman Charitable Trust; and funding from the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and the Albertson Parkinson's Research Foundation. He serves as principal investigator (PI) or co‐PI for Biohaven Pharmaceuticals, Inc. (BHV4157‐206 and BHV3241‐301); Neuraly, Inc. (NLY01‐PD‐1); and Vigil Neuroscience, Inc. (VGL101‐01.001 and VGL101‐01.002) grants. He serves as co‐PI of the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for Vigil Neuroscience, Inc. Funding Information: Funding agencies: Funding for this work was provided by Mayo Clinic Center for Regenerative Medicine and Donald G. and Jodi P. Heeringa Family Funding Information: R.H.A.‐S. receives partial funding from Mayo Clinic internal research funds and is partially funded by Donald G. and Jodi P. Heeringa Family. ",

year = "2022",

month = may,

doi = "10.1002/mds.29008",

language = "English (US)",

volume = "37",

pages = "1120--1121",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Comment on

T2 - Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood

AU - Hanna AL-Shaikh, Rana

AU - Jansen-West, Karen R.

AU - Petrucelli, Leonard

AU - Wszolek, Zbigniew K.

AU - Prudencio, Mercedes

N1 - Funding Information: Z.K.W. receives partial funding from NIH/NIA and NIH/NINDS (1U19AG063911, FAIN: U19AG063911), Mayo Clinic Center for Regenerative Medicine, Mayo Clinic in Florida Focused Research Team Program; gifts from The Sol Goldman Charitable Trust; and funding from the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and the Albertson Parkinson's Research Foundation. He serves as principal investigator (PI) or co‐PI for Biohaven Pharmaceuticals, Inc. (BHV4157‐206 and BHV3241‐301); Neuraly, Inc. (NLY01‐PD‐1); and Vigil Neuroscience, Inc. (VGL101‐01.001 and VGL101‐01.002) grants. He serves as co‐PI of the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for Vigil Neuroscience, Inc. Funding Information: Funding agencies: Funding for this work was provided by Mayo Clinic Center for Regenerative Medicine and Donald G. and Jodi P. Heeringa Family Funding Information: R.H.A.‐S. receives partial funding from Mayo Clinic internal research funds and is partially funded by Donald G. and Jodi P. Heeringa Family.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85130348049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130348049&partnerID=8YFLogxK

U2 - 10.1002/mds.29008

DO - 10.1002/mds.29008

M3 - Letter

C2 - 35587620

AN - SCOPUS:85130348049

SN - 0885-3185

VL - 37

SP - 1120

EP - 1121

JO - Movement Disorders

JF - Movement Disorders

IS - 5

ER -

Comment on: Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this